Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease
Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal Clinical Ophthalmology. The publication is accessible on the National Institutes of Health (NIH) website here.
The results from the study show that the change from baseline to Day 29 in the global ocular discomfort score, the primary efficacy endpoint, was statistically significantly greater for topical ocular licaminlimab (OCS-02) (-7.9) than for vehicle (-3.6) (90% CI -7.7, -0.8; p = 0.041). The percentage of patients with an improvement in global ocular discomfort score >20 from baseline to treatment day 29, one of the main secondary efficacy endpoints, was statistically greater for licaminlimab (17.9%) compared to vehicle (4.7%) (P=0.018).
Licaminlimab (OCS-02) was well tolerated in this study, with no major safety differences between licaminlimab (OCS-02) and vehicle treatment groups, and no increase in intra-ocular pressure was observed.
Licaminlimab (OCS-02) is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFα, with dual mechanism of action (MoA), anti-inflammation and anti-necrosis. Unlike full-length monoclonal antibodies, scFv fragments can penetrate ocular surface tissues when used as eye drops, due to the smaller size of the molecule giving it the potential to become the first approved topical biologic for DED.
Licaminlimab (OCS-02) is currently being investigated by Oculis in phase 2 clinical trials for the treatment of dry eye disease and uveitis.
“There is a true unmet medical need for the development of drugs with new MOA to treat the inflammation involved in the pathogenesis of DED. OCS-02 is certainly one that could fill that gap," Pr Christophe Baudouin, MD, Professor of Ophthalmology and Chairman of Ophthalmology III in Quinze-vingts National Ophthalmology Hospital, Paris, said in a company news release. "As compared to currently available treatment options and other product candidates in the DED pipeline, OCS-02 could play a role in the treatment of the underlying causes of the disease given its anti-inflammatory and anti-necrosis benefits. I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options.”
“The phase 2 data further reinforce our confidence in the potential of OCS-02 as a novel anti-inflammatory treatment for the effective management of dry eye disease, but also for other inflammatory eye diseases," said Riad Sherif, MD, CEO of Oculis. "With phase 2b clinical trials of OCS-02 for the treatment of dry eye disease and uveitis, which are planned to start in the coming months, along with ongoing phase 3 clinical trials of OCS-01 in diabetic macular edema and inflammation and pain following ocular surgery and a proof-of-concept (POC) trial of OCS-05 in acute optic neuritis, we look forward with confidence to the further development of the Oculis ophthalmology franchise to address significant unmet medical needs in key areas of ophthalmology.”